Bryan JT Source Vaccine and Biologics Research, Merck Research Laboratories, Merck & Co., Inc., West Point, PA, United States. firstname.lastname@example.org Abstract The challenges of the journey from target identification through development of a prophylactic quadrivalent human papillomavirus (HPV) vaccine have been met in Gardasil. Cervical cancer is the second leading cause of cancer-related death in […]
What important information about GARDASIL should I know? You should continue to get routine cervical cancer screening. GARDASIL may not fully protect everyone who gets the vaccine. GARDASIL will not protect against HPV types that you already have. Who should not get GARDASIL? You should not get GARDASIL if you have, or have had: […]
This study is currently recruiting participants. Verified by Emory University, February 2010 Official Title Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents Purpose African American adolescent females seeking treatment for STIs are an underserved population at increased risk for HPV infection. While GARDASIL is an effective preventive vaccine, vaccination rates are low. […]
This study is not yet open for participant recruitment. Verified by Desmond Tutu HIV Centre, July 2009 Official Title Preparing for Adolescent HIV Vaccine Trials in South Africa: a Multi-centre Study to Evaluate Acceptability of the HPV Vaccine in Adolescents Purpose This study will use the licensed HPV vaccine, Gardasil, as a surrogate for an […]
Note from SaneVax: Study on barriers to HPV vaccine uptake. Psychological, financial, perception of need? Could it possibly be adverse events?